지연성 운동이상증 치료제 시장 예측 : 제품 유형, 질환 유형, 투여 경로, 유통 채널 및 지역별 분석(-2034년)

According to Stratistics MRC, the Global Tardive Dyskinesia Therapeutics Market is accounted for $3.4 billion in 2026 and is expected to reach $8.0billion by 2034 growing at a CAGR of 11.1% during the forecast period. A drug-induced movement condition called tardive dyskinesia (TD) results in uncontrollably moving the tongue, face, torso, and limbs. It is a side effect brought on by extended use of specific psychiatric drug classes, such antipsychotics. Although they sometimes afflict other patients as well, the illness is most frequent among those who have been taken long-term antipsychotic drugs for schizophrenia, schizoaffective disorder, or bipolar disorder.

According to an article published by John Wiley & Sons, Inc., in August 2022, the prevalence of tardive dyskinesia in Europe is 23.3% amongst psychiatric patients receiving treatment with antipsychotics.

Market Dynamics:

Driver:

Rising prevalence of tardive dyskinesia

Increased consciousness encourages early identification and action, which may lessen the severity of symptoms. Research progresses lead to the creation of more specialized drugs and therapies, providing impacted people with more individualized care. Furthermore, greater awareness encourages financing for additional research, which spurs creativity and reveals fresh approaches to tardive dyskinesia therapy and prevention, eventually enhancing the quality of life for individuals affected by the disorder.

Restraint:

Complexity in management

The management of tardive dyskinesia frequently entails a mix of strategies, such as changing current prescriptions or adding new ones. This intricacy can make treatment difficult, particularly when juggling the requirement to manage the underlying condition for which the original medication was prescribed. Therapeutic options for management have a range of side effects, from mild to severe, which may require close monitoring and management.

Opportunity:

Increased awareness and diagnosis

Early detection enables timely management, which may slow its course and enhance patient outcomes. Increased knowledge encourages healthcare professionals to monitor patients proactively, which makes it easier to control symptoms by promptly changing prescription schedules or using other therapies. Moreover, better knowledge promotes patient education and support, lessens stigma, and encourages a more compassionate approach to healthcare. This all-encompassing strategy eventually improves people's quality of life, which fuels market expansion.

Threat:

Limited R&D investment by pharmaceutical companies

One of the major challenges of rare disease drugs in terms of research and development is the small patient population available for clinical trials. Only a few hundred or few thousand patients with rare diseases are accessible for clinical trials. Rare diseases afflict a tiny population. Furthermore, because research may be expensive and have hazy returns on investment, pharmaceutical corporations could be reluctant to fund it.

Covid-19 Impact:

The pandemic caused disruptions in healthcare services globally, affecting regular check-ups, access to specialists, and availability of in-person treatments. This led to delays or interruptions in treatment for many individuals with tardive dyskinesia. COVID-19 impacted the progress of ongoing clinical trials and research studies related to tardive dyskinesia. Some trials might have been delayed or modified due to restrictions on in-person visits and enrollment challenges.

The deutetrabenazine segment is expected to be the largest during the forecast period

The deutetrabenazine segment is expected to be the largest during the forecast period. Its deuterium substitution enhances its efficacy and safety profile by prolonging its half-life, leading to fewer dose-related side effects and improved patient adherence. This compound demonstrates potential in reducing involuntary movements associated with Tardive Dyskinesia while offering a more consistent and manageable treatment approach.

The tardive dystonia segment is expected to have the highest CAGR during the forecast period

The tardive dystonia segment is expected to have the highest CAGR during the forecast period. Tardive dystonia, a subtype of tardive dyskinesia, specifically involves sustained muscle contractions causing repetitive, twisting movements or abnormal postures. Sometimes, adjusting or discontinuing the medications that trigger tardive dystonia can lead to improvement or resolution of symptoms. However, this must be carefully managed by a healthcare professional to balance the benefits of the medication with the risk of worsening psychiatric conditions.

Region with largest share:

North America is projected to hold the largest market share during the forecast period. Several pharmaceutical companies have been investing in developing medications specifically targeted to manage symptoms. These treatments aim to alleviate the involuntary movements associated with the condition, thereby improving the quality of life for affected individuals. The market has shown growth in terms of advancements in therapeutic options and the growing acceptance of these treatments among healthcare providers.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period due to rising healthcare awareness, improving diagnostic techniques, and an aging population. Pharmaceutical companies were working on developing new treatments and medications targeting symptoms, aiming to address the unmet medical needs in this area. Collaborations between local and global pharmaceutical companies, as well as advancements in technology for diagnosis and treatment, were also contributing to the expansion of the market in the region.

Key players in the market

Some of the key players in Tardive Dyskinesia Therapeutics market include Mitsubishi Tanabe Pharma Corporation, Luye Pharma Group, Teva Pharmaceutical Industries Ltd., Neurocrine Biosciences, Inc., SOM BIOTECH, Sun Pharmaceutical Industries Ltd, AbbVie Inc , Sanis, SteriMax Inc., Adamas Pharmaceuticals, Inc , Reddys Laboratories Ltd, Mylan N.V., Bausch Health, Johnson & Johnson Services, Lupin Pharmaceuticals Inc, Novartis AG, Baxter, Amgen Inc, Pfizer Inc and Medicure Inc.

Key Developments:

In February 2023, Teva Pharmaceuticals announced the print publication of the IMPACT-TD Scale, an easy-to-use, standardized and clinician-rated assessment. The scale, developed by a consensus panel, will assist healthcare providers in determining the impact of tardive dyskinesia (TD) on different aspects of a patient's daily functioning.

In December 2021, Mitsubishi Tanabe Pharma Corporation and Janssen Pharmaceutical K.K. have entered into a co-promotion agreement for MT-5199, a vesicular monoamine transporter type 2 (VMAT2) inhibitor, which is intended for use as tardive dyskinesia therapeutics in Japan.

Product Types Covered:

• Valbenazine
• Deutetrabenazine
• Clonazepam
• Vitamin E
• Benzodiazepines
• Ondansetron
• Tetrabenazine
• Reserpine
• Propranolol
• Dopamine-Depleting Agents

Disease Types Covered:

• Tardive akathisia
• Tardive Orofacial Dyskinesia
• Tardive Dystonia
• Tardive Blepharospasm
• Tardive Tics

Route Of Administration Covered:

• Oral
• Injectable

Distribution Channels Covered:

• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies
• Other Distribution Channels

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Tardive Dyskinesia Therapeutics Market, By Product Type

• 5.1 Introduction
• 5.2 Valbenazine
• 5.3 Deutetrabenazine
• 5.4 Clonazepam
• 5.5 Vitamin E
• 5.6 Benzodiazepines
• 5.7 Ondansetron
• 5.8 Tetrabenazine
• 5.9 Reserpine
• 5.10 Propranolol
• 5.11 Dopamine-Depleting Agents

6 Global Tardive Dyskinesia Therapeutics Market, By Disease Type

• 6.1 Introduction
• 6.2 Tardive akathisia
• 6.3 Tardive Orofacial Dyskinesia
• 6.4 Tardive Dystonia
• 6.5 Tardive Blepharospasm
• 6.6 Tardive Tics

7 Global Tardive Dyskinesia Therapeutics Market, By Route Of Administration

• 7.1 Introduction
• 7.2 Oral
• 7.3 Injectable

8 Global Tardive Dyskinesia Therapeutics Market, By Distribution Channel

• 8.1 Introduction
• 8.2 Hospital Pharmacies
• 8.3 Drug Stores & Retail Pharmacies
• 8.4 Online Pharmacies
• 8.5 Other Distribution Channels

9 Global Tardive Dyskinesia Therapeutics Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Product Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 Mitsubishi Tanabe Pharma Corporation
• 11.2 Luye Pharma Group
• 11.3 Teva Pharmaceutical Industries Ltd.
• 11.4 Neurocrine Biosciences, Inc.
• 11.5 SOM BIOTECH
• 11.6 Sun Pharmaceutical Industries Ltd
• 11.7 AbbVie Inc
• 11.8 Sanis
• 11.9 SteriMax Inc.
• 11.10 Adamas Pharmaceuticals, Inc
• 11.11 Reddys Laboratories Ltd
• 11.12 Mylan N.V.
• 11.13 Bausch Health
• 11.14 Johnson & Johnson Services
• 11.15 Lupin Pharmaceuticals Inc
• 11.16 Novartis AG
• 11.17 Baxter
• 11.18 Amgen Inc
• 11.19 Pfizer Inc
• 11.20 Medicure Inc